المملكة: “Food and Medicine” adopts a “vanavra” to treat kidney disease

Promising medicines

The authority’s approval to include the preparation in the promising medicine path based on the results of clinical studies that showed a significant decrease in the protein rate in the urine, and a remarkable improvement in the indicators of kidney function, compared to imaginary therapy, which opens the door for hope for a group of patients who lack effective treatment options.
The authority confirmed that this appointment is not an official registration for the drug, but rather allows the company to apply for the registration file within a special path directed to medicines that show preliminary results encouraging to treat rare or serious diseases, and the authority will announce later on the registration decision after completing the technical evaluation procedures in accordance with the organized regulations.
The “Promising Medicines” program is one of the strategic initiatives of the authority to support the access of innovative treatments for patients in the shortest possible time, as it is required that the drug target serious or life -threatening diseases, and shows the effectiveness of exceeding the available traditional treatments, and it was not previously registered with any supervisory authority when submitting the application.
The authority continues its efforts to accelerate the availability of qualitative treatments and raise the level of therapeutic innovation in the Kingdom, which contributes to improving the quality of life for patients, and enhancing the efficiency of the national health system.